Publication
CGRP-targeted medication in chronic migraine - systematic review
| dc.contributor.author | Oliveira, Renato | |
| dc.contributor.author | Gil-Gouveia, Raquel | |
| dc.contributor.author | Puledda, Francesca | |
| dc.date.accessioned | 2024-04-17T12:17:34Z | |
| dc.date.available | 2024-04-17T12:17:34Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | BACKGROUND: Chronic migraine is a highly debilitating condition that is often difficult to manage, particularly in the presence of medication overuse headache. Drugs targeting the calcitonin gene-related peptide (CGRP), or its receptor have shown promising results in treating this disorder. METHODS: We searched Pubmed and Embase to identify randomized clinical trials and real-world studies reporting on the use of medication targeting the calcitonin gene-related peptide in patients with chronic migraine. RESULTS: A total of 270 records were identified. Nineteen studies qualified for the qualitative analysis. Most studies reported on monoclonal antibodies targeting CGRP (anti-CGRP mAbs), that overall prove to be effective in decreasing monthly migraine days by half in about 27.6-61.4% of the patients. Conversion from chronic to episodic migraine was seen in 40.88% of the cases, and 29-88% of the patients stopped medication overuse. Obesity seems to be the main negative predictor of response to anti-CGRP mAbs. There is no evidence to suggest the superiority of one anti-CGRP mAb. Despite the lack of strong evidence, the combination of anti-CGRP medication with onabotulinumtoxinA in chronic migraine is likely to bring benefits for resistant cases. Atogepant is the first gepant to demonstrate a significant decrease in monthly migraine days compared to placebo in a recent trial. Further, anti-CGRP mAb and gepants have a good safety profile. CONCLUSION: There is strong evidence from randomized trials and real-world data to suggest that drugs targeting CGRP are a safe and effective treatment for chronic migraine. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.doi | 10.1186/s10194-024-01753-y | pt_PT |
| dc.identifier.eid | 85190071412 | |
| dc.identifier.issn | 1129-2369 | |
| dc.identifier.pmc | PMC10996229 | |
| dc.identifier.pmid | 38575868 | |
| dc.identifier.uri | http://hdl.handle.net/10400.14/44653 | |
| dc.identifier.wos | 001197170200001 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | Anti-CGRP | pt_PT |
| dc.subject | CGRP | pt_PT |
| dc.subject | Chronic migraine | pt_PT |
| dc.subject | Medication overuse | pt_PT |
| dc.subject | Migraine | pt_PT |
| dc.title | CGRP-targeted medication in chronic migraine - systematic review | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 1 | pt_PT |
| oaire.citation.title | The journal of headache and pain | pt_PT |
| oaire.citation.volume | 25 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |